Humulin R

Humulin R

Manufacturer:

Eli Lilly

Distributor:

Zuellig
The information highlighted (if any) are the most recent updates for this brand.
Full Prescribing Info
Contents
Regular human insulin (recombinant DNA origin).
Description
Cartridge: Humulin R contains regular human insulin.
Vial: Each vial of Regular Insulin Human (rDNA origin) (Humulin R) contains 100 IU/mL.
Regular Insulin Human (rDNA origin) (Humulin R) is a sterile solution. It consists of zinc-insulin crystals dissolved in a clear fluid. Regular Insulin Human(rDNA origin) (Humulin R) has had nothing added to change the speed or length of its action.
It takes effect rapidly and has a relatively short duration of activity (4 to 12 hours) as compared with other insulins.
KwikPen: 1 mL contains 100 IU human insulin (produced in E. coli by recombinant DNA technology).
One prefilled pen contains 3 mL equivalent to 300 IU of soluble insulin.
Excipients/Inactive Ingredients:
m-cresol, Glycerol, Water for injections.
The following may be used to adjust pH; Hydrochloric acid and/or Sodium hydroxide.
Action
Pharmacology: Cartridge: The time course of action of any insulin may vary considerably in different individuals or at different times in the same individual. As with all insulin preparations, the duration of action of Humulin is dependent on dose, site of injection, blood supply, temperature and physical activity.
Humulin R is a neutral human insulin of recombinant DNA origin. It is a short-acting preparation; onset of action occurs at approximately 30 min, with a duration of about 5 hrs and peak activity at 1-3 hrs.
Vial: Insulin Human (Humulin) is synthesized in a special non-disease-producing laboratory strain of Escherichia coli bacteria that has been genetically altered by the addition of the gene for human insulin production. The time course of action of any insulin may vary considerably in different individuals or at different times in the same individual. As with all insulin preparations, the duration of action of Insulin Human (Humulin), is dependent on dose, site of injection, blood supply, temperature, and physical activity.
Pharmacodynamics: KwikPen: Humulin R is a rapidly-acting insulin preparation.
The prime activity of insulin is the regulation of glucose metabolism.
In addition, insulin has several anabolic and anti-catabolic actions on a variety of different tissues. Within muscle tissue this includes increasing glycogen, fatty acid, glycerol and protein synthesis and amino acid uptake, while decreasing glycogenolysis, gluconeogenesis, ketogenesis, lipolysis, protein catabolism and amino acid output. The typical activity profile (glucose utilization curve) following subcutaneous injection is illustrated below by the heavy line. Variations that a patient may experience in timing and/or intensity of insulin activity are illustrated by the shaded area. Individual variability will depend on factors such as size of dose, site of injection temperature and physical activity of the patient. (See figure.)

Click on icon to see table/diagram/image

Pharmacokinetics: The pharmacokinetics of insulin do not reflect the metabolic action of that hormone. Therefore, it is more appropriate to examine glucose utilization curves (as discussed previously) when considering the activity of insulin.
Toxicology: Preclinical safety data: Humulin is human insulin produced by recombinant technology. No serious events have been reported in subchronic toxicology studies. Human insulin was not mutagenic in a series of in vitro and in vivo genetic toxicity assays.
Indications/Uses
For the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis.
Dosage/Direction for Use
The dosage should be determined according to the individual requirements of the patient.
New Patients: New patients can be started on Humulin in the same manner as they would be on animal-source insulin. Patients should be monitored closely during the adjustment period.
Transfer Patients: When transferring patients, most patients should be initiated at the same dose and dosage schedule. However, when a patient on high doses of animal insulin is initiated to Humulin R, it is appropriate to reduce the starting dosage and monitor the patient carefully.
Administration: Given by SC or IV injection.
Vial: Dosage schedule has been individualized for each patient, because each case of diabetes is different. Consult a physician on the type of insulin, dosage strength and when to inject the insulin.
The usual insulin dose may be affected by changes in food intake, activity or work schedule. The patient should carefully follow the physician's instructions to allow for these changes. Other things that may affect the insulin dose are: Illness: Illness, especially with nausea and vomiting, may cause insulin requirements to change. Even if the patient is not eating, insulin will still be required. The patient and the physician should establish a sick-day plan to use in case of illness. When sick, test blood/urine frequently and the patient should consult physician as instructed.
Pregnancy: Good control of diabetes is especially important for the patient and the unborn baby. Pregnancy may make managing diabetes more difficult. If planning to be pregnant, already pregnant, or nursing a baby, consult a doctor.
Medication: Insulin requirements may be increased if the patient is taking other drugs with hyperglycemic activity, such as oral contraceptives, corticosteroids, or thyroid replacement therapy. Insulin requirements may be reduced in the presence of drugs with hypoglycemic activity, such as oral hypoglycemics, salicylates (for example, aspirin), sulfa antibiotics, and certain antidepressants. Always discuss any medications that are being taken to the doctor (see also PRECAUTIONS).
Exercise: Exercise may lower the body's need for insulin during and for some time after the activity. Exercise may also speed up the effect of an insulin dose, especially if the exercise involves the area of injection site (eg, the leg should not be used for injection just prior to running). Discuss with the physician how to adjust dosage regimen to accommodate exercise.
Travel: Persons traveling across more than 2 time zones should consult their doctor concerning adjustments in their insulin schedule.
KwikPen: The dosage should be determined by the physician, according to the requirement of the patient.
Humulin R should be given by subcutaneous injection but may, although not recommended, also be given by intramuscular injection. It may also be administered intravenously.
Subcutaneous administration should be in the upper arms, thighs, buttocks or abdomen. Use of injection sites should be rotated so that the same site is not used more than approximately once a month.
Care should be taken when injecting any Humulin insulin preparations to ensure that a blood vessel has not been entered. After any insulin injection, the injection site should not be massaged. Patients must be educated to use proper injection techniques.
Humulin Mixture formulation is a ready-made defined mixture of soluble and isophane insulin designed to avoid the need for the patient to mix insulin preparations. A patient's treatment regimen should be based on their individual metabolic requirements.
Each pack contains a patient information leaflet with instructions on how to inject insulin.
Overdosage
Symptoms: Overdosage causes hypoglycemia with accompanying symptoms that include listlessness, confusion, palpitations, sweating and vomiting.
Treatment: Mild hypoglycemic episodes will respond to oral administration of glucose or sugar and rest. Correction of moderately severe hypoglycemia can be accomplished by the IM or SC administration of glucagon. If the patient is comatose, IV administration of dextrose injection is required.
KwikPen: Insulin has no specific overdose definitions, because serum glucose concentrations are a result of complex interactions between insulin levels, glucose availability and other metabolic processes. Hypoglycemia may occur as a result of an excess of insulin relative to food intake and energy expenditure.
Hypoglycemia may be associated with listlessness, confusion, palpitations, headache, sweating and vomiting.
Mild hypoglycemic episodes will respond to oral administration of glucose or sugar products.
Correction of moderately severe hypoglycemia can be accomplished by intramuscular or subcutaneous administration of glucagon, followed by oral carbohydrate when the patient recovers sufficiently. Patients who fail to respond to glucagon must be given glucose solution intravenously.
If the patient is comatose, glucagon should be administered intramuscularly or subcutaneously. However, glucose solution must be given intravenously, if glucagon is not available or if the patient fails to respond to glucagon. The patient should be given a meal as soon as consciousness is recovered.
Sustained carbohydrate intake and observation may be necessary because hypoglycemia may occur after apparent clinical recovery.
Contraindications
Protamine zinc and isophane insulin, and insulin zinc suspensions should never be given IV and are not indicated for hyperglycemic coma.
Hypoglycemia.
KwikPen: Hypersensitivity to Insulin Human (Humulin) or to the formulation excipients, unless used as part of a desensitization program.
Under no circumstances should any Insulin Human (Humulin) formulation other than Soluble Insulin Human (Humulin R) be given intravenously.
Warnings
Humulin, a human insulin product, differs from animal-source insulins because it is structurally identical to the insulin produced by the body's pancreas and because of its unique manufacturing process.
Any change of insulin should be made cautiously and only under medical supervision. Changes in refinement, purity, strength, brand (manufacturer), type (regular, NPH, Lente, etc), species (beef, pork, beef-pork, human), and/or method of manufacture (recombinant DNA versus animal-source insulin) may result in the need for a change in dosage.
Some patients taking Humulin products may require a change in dosage from that used with animal-source insulins. If an adjustment is needed, it may occur with the first dose or during the first several weeks or months.
Special Precautions
Vial and KwikPen: Thiazolidinediones (TZDs) used in combination with Insulin: TZDs in combination with insulin, are associated with an increase risk of edema and heart failure; especially in patients with underlying cardiac disease.
Vial: Hyperglycemia and Diabetic Acidosis: Hyperglycemia (too much glucose in the blood) may develop if the body has too little insulin.
Hyperglycemia can be brought about by: Omitting insulin intake or taking less than the physician has prescribed; eating significantly more than the suggested meal plan and developing fever, infection or other significant stressful situation.
In patients with insulin-dependent diabetes, prolonged hyperglycemia can result in diabetic acidosis. The first symptoms of diabetic acidosis usually come on gradually over a period of hours or days, and include a drowsy feeling, flushed face, thirst, loss of appetite and fruity odor of the breath. With acidosis, urine tests show large amounts of glucose and acetone. Heavy breathing and rapid pulse are more severe symptoms. If uncorrected, prolonged hyperglycemia or diabetic acidosis can lead to nausea, vomiting, dehydration, loss of consciousness or death. Therefore, it is important that the patient obtain medical assistance immediately.
Lipodystrophy: Rarely, administration of insulin subcutaneously can result in lipoatrophy (depression in the skin) or lipohypertrophy (enlargement or thickening of tissue). If either of these conditions is noticed, consult a physician. A change in the injection technique may help alleviate the problem.
Allergy to Insulin: Local Allergy: Patients occasionally experience redness, swelling and itching at the site of injection of insulin. This condition, called local allergy, usually clears up in a few days to a few weeks. In some instances, this condition may be related to factors other than insulin eg, irritants in the skin cleansing agent or poor injection technique. If local reactions occur, consult a physician.
Systemic Allergy: Less common, but potentially more serious, is generalized allergy to insulin, which may cause rash over the whole body, shortness of breath, wheezing, reduction in blood pressure, fast pulse or sweating. Severe cases of generalized allergy may be life-threatening. If generalized allergic reaction to insulin occur, notify a physician immediately.
Spontaneous Data: Cases of edema have been reported with insulin therapy, particularly if previous poor metabolic control is improved by intensified therapy.
Use in pregnancy: Good control of diabetes is especially important for the patient and the unborn baby. Pregnancy may make managing diabetes more difficult. If planning to be pregnant, already pregnant, or nursing a baby, consult a physician.
KwikPen: Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type (soluble, isophane, mixture), species (animal, human, human insulin analogue), and/or method of manufacture (recombinant DNA versus animal-source insulin) may result in the need for a change in dosage.
Some patients taking human insulin may require a change in dosage from that used with animal-source insulins. If an adjustment is needed, it may occur with the first dose or during the first several weeks or months.
A few patients who experienced hypoglycemic reactions after transfer to human insulin have reported that the early warning symptoms were less pronounced or different from those experienced with their previous animal insulin. Patients whose blood glucose is greatly improved, e.g. by intensified insulin therapy, may lose some or all of the warning symptoms of hypoglycemia and should be advised accordingly. Other conditions which may make the early warning symptoms of hypoglycemia may be different or less pronounced include long duration of diabetes, diabetic nerve disease, medications such as beta-blockers. Uncorrected hypoglycemic and hyperglycemic reactions can cause loss of consciousness, coma or death.
The use of dosages which are inadequate or discontinuation of treatment, especially in insulin-dependent diabetics, may lead to hyperglycemia and diabetic ketoacidosis; conditions which are potentially lethal.
Treatment with human insulin may cause formation of antibodies, but titers of antibodies are lower than those to purified animal insulin.
Insulin requirements may change significantly in diseases of the adrenal, pituitary or thyroid glands and in the presence of renal or hepatic impairment. Insulin requirements may be increased during illness or emotional disturbances. Adjustment of insulin dosage may also be necessary if patients change their level of physical activity or change their usual diet.
Effects on ability to drive and use machines: The patient's ability to concentrate and react may be impaired as a result of hypoglycemia. This may constitute a risk in situations where these abilities are of special importance (e.g., driving a car or operating machinery).
Patients should be advised to take precautions to avoid hypoglycemia whilst driving; this is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycemia or have frequent episodes of hypoglycemia. The advisability of driving should be considered in these circumstances.
Use In Pregnancy & Lactation
Pregnancy: Vial: Good control of diabetes is especially important for the patient and the unborn baby. Pregnancy may make managing diabetes more difficult. If planning to be pregnant, already pregnant, or nursing a baby, consult a physician.
KwikPen: It is essential to maintain good control of the insulin treated (insulin-dependent or gestational diabetes) patient throughout pregnancy. Insulin requirements usually fall during the first trimester and increase during the second and third trimesters. Patients with diabetes should be advised to inform their doctors if they are pregnant or are contemplating pregnancy.
Careful monitoring of glucose control, as well as general health, is essential in pregnant patients with diabetes.
Patients with diabetes who are lactating may require adjustments in insulin dose and/or diet.
Adverse Reactions
Vial: Hypoglycemia (Insulin Reaction): Hypoglycemia (too little glucose in the blood) is one of the most frequent adverse events experienced by insulin users. It can be brought about by: Taking too much insulin; missing or delaying meals; exercising or working more than usual; an infection or illness (especially with diarrhea or vomiting); a change in the body's need for insulin; diseases of the adrenal, pituitary or thyroid gland, or progression of kidney or liver disease; interactions with other drugs that lower blood glucose eg, oral hypoglycemics, salicylates (eg, aspirin), sulfa antibiotics and certain antidepressants; consumption of alcoholic beverages.
Symptoms of mild to moderate hypoglycemia may occur suddenly and can include: sweating, dizziness, palpitation, tremor, hunger, restlessness, tingling in the hands, feet, lips or tongue, lightheadedness, inability to concentrate, headache, drowsiness, sleep disturbances, anxiety, blurred vision, slurred speech, depressive mood, irritability, lightheadedness, inability to concentrate, headache, abnormal behavior, unsteady movement and personality changes.
Signs of severe hypoglycemia can include: Disorientation, unconsciousness, seizures and death.
Therefore, it is important that assistance be obtained immediately.
Early warning symptoms of hypoglycemia may be different or less pronounced under certain conditions eg, long duration of diabetes, diabetic nerve disease, medications eg, beta-blockers, change in insulin preparations, intensified control (3 or more insulin injections per day) of diabetes.
A few patients who have experienced hypoglycemic reactions after transfer from animal-source insulin to human insulin have reported that the early warning symptoms of hypoglycemia were less pronounced or different from those experienced with their previous insulin.
Without recognition of early warning symptoms, the patient may not be able to take steps to avoid more serious hypoglycemia. Be alert for all the various types of symptoms that may indicate hypoglycemia. Patients who experience hypoglycemia without early warning symptoms should monitor their blood glucose frequently, especially prior to activities eg, driving. If the blood glucose is below the normal fasting glucose, consider eating or drinking sugar-containing foods to treat hypoglycemia.
Mild to moderate hypoglycemia may be treated by eating foods or drinks that contain sugar. Patients should always carry a quick source of sugar eg, candy mints or glucose tablets. More severe hypoglycemia may require the assistance of another person. Patients who are unable to take sugar orally or who are unconscious require an injection of glucagon or should be treated with IV administration of glucose at a medical facility.
The patient should learn to recognize the symptoms of hypoglycemia. If uncertain about these symptoms, the patient should monitor his/her blood glucose frequently to help him/her learn to recognize the symptoms that the patient experiences with hypoglycemia.
If the patient has frequent episodes of hypoglycemia or experience difficulty in recognizing the symptoms, he/she should consult the physician to discuss possible changes in therapy, meal plans and/or exercise programs to help avoid hypoglycemia.
KwikPen: Hypoglycemia is the most frequent undesirable effect of insulin therapy that a patient with diabetes may suffer. Severe hypoglycemia may lead to loss of consciousness, and in extreme cases, death. No specific frequency for hypoglycemia is presented, since hypoglycemia is a result of both the insulin dose and other factors e.g. a patient's level of diet and exercise.
Local allergy in patients is common (1/100 to < 1/10). Redness, swelling, and itching can occur at the site of insulin injection. This condition usually resolves in a few days to a few weeks. In some instances, local reactions may be related to factors other than insulin, such as irritants in the skin cleansing agent or poor injection technique.
Systemic allergy, which is very rare (< 1/10,000) but potentially more serious, is a generalized allergy to insulin. It may cause rash over the whole body, shortness of breath, wheezing, reduction in blood pressure, fast pulse, or sweating. Severe cases of generalized allergy may be life-threatening. In the rare event of a severe allergy to Insulin Human (Humulin), treatment is required immediately. A change of insulin or desensitization may be required.
Lipodystrophy at the injection site is uncommon (1/1,000 to < 1/100). Spontaneous data: Cases of edema have been reported with insulin therapy, particularly if previous poor metabolic control is improved by intensified insulin therapy (see Precautions).
Drug Interactions
The addition of corticosteroids, diuretics of thiazide, furosemide or ethacrynic acid type, oral contraceptives or thyroid replacement therapy to the patient's treatment may lead to an increase in insulin requirements. The addition of MAOI may necessitate an adjustment of insulin dosage.
Insulin requirements may be reduced in the presence of drugs with hypoglycemic activity, eg oral hypoglycemics, salicylates (eg, aspirin), sulfa antibiotics and certain antidepressants. Always discuss any medications the patient is taking with the physician.
The concomitant use of a β-adrenergic-blocking agent (particularly a noncardioselective agent) may mask the symptoms of and delay recovery from, hypoglycemia. Hypoglycemia in the presence of concomitant use of a β-adrenergic-blocking agent may precipitate a hypertensive crisis.
KwikPen: Some medicinal products are known to interact with glucose metabolism.
The physician should take possible interactions into account and ask patients about their other medications in addition to human insulin.
Insulin requirements may be increased by substances with hyperglycemic activity, such as glucocorticoids, thyroid hormones, growth hormone, danazol, beta2-sympathomimetics (such as ritodrine, salbutamol, terbutaline), thiazides.
Insulin requirements may be reduced in the presence of substances with hypoglycemic activity, such as oral hypoglycemics (OHA), salicylates (for example, acetylsalicylic acid), certain antidepressants (monoamine oxidase inhibitors), certain angiotensin converting enzyme (ACE) inhibitors (captopril, enalapril), angiotensin II receptor blockers, non-selective beta-blocking agents and alcohol. Somatostatin analogues (octreotide, lanreotide) may both decrease or increase insulin dose requirements.
Caution For Usage
Humulin R consists of zinc insulin crystals dissolved in a clear fluid. It is clear and colorless. Humulin R should not be used if it is cloudy, unusually viscous, precipitated or even slightly colored.
KwikPen: Incompatibilities: Humulin preparations should not be mixed with insulins produced by other manufacturers or with animal insulin preparations.
Special precautions for disposal and other handling: Do not reuse needles. Dispose of the needle in a responsible manner. Needles and pens must not be shared. Cartridges/Prefilled pens (KwikPen) can be used until empty, then properly discard. Any unused product or waste material should be disposed of in accordance with local requirements.
a) Preparing a dose: Prefilled insulin delivery devices containing soluble insulin injection (Humulin R) do not require re-suspension. Soluble insulin injection is a clear and colorless liquid with a waterlike appearance and consistency. Do not use insulin human injection or soluble insulin injection if it appears cloudy, thickened, or slightly colored or if solid particles are visible.
Insulin should look uniformly cloudy or milky after mixing. If not, repeat the above steps until the contents are mixed. Prefilled insulin delivery devices should be examined frequently. Do not use if the insulin substance (the white material) remains visibly separated from the liquid after mixing. Do not use if there are clumps in the insulin after mixing. Do not use if solid white particles stick to the bottom or wall of the cartridge, giving a frosted appearance.
Prepare your syringe prior to injection, as directed by your doctor or diabetes specialist nurse.
Use an insulin syringe marked for the strength of insulin being administered. Follow the instructions with Humulin R KwikPen for attaching the needle and administering the insulin injection.
For Humulin R KwikPen, a needle must always be attached before priming, dialing, and injecting an insulin dose. It should always be primed before each injection. Failure to prime may result in an inaccurate dose. For complete instructions on how to administer insulin, refer to the manufacturer's instruction for the insulin delivery device.
b) Injecting a dose: Inject the correct dose of insulin, as directed by your doctor or diabetes specialist nurse.
Use of the injection sites should be rotated so that the same is not used more than approximately once a month.
Storage
Humulin should be stored between 2°C and 8°C. It should not be exposed to excessive heat or sunlight and should never be frozen.
Vial: If refrigeration is not possible, the bottle of insulin currently used can be kept unrefrigerated as long as it is kept as cool as possible [below 86°F (30°C)] and away from heat and light.
The vial in use may be kept at room temperature (maximum 25°C) for 1 month.
Patient Counseling Information
Vial: Instructions for Use: Always check the appearance of bottle of insulin before using, and anything unusual in the appearance of insulin or insulin requirements is markedly changing, consult the doctor.
It is a clear and colorless liquid with a water-like appearance and consistency. Do not use if it appears cloudy, thickened, or slightly colored or if solid particles are visible.
Injections Procedures: Correct Syringe: Doses of insulin are measured in units. It is important that you understand the markings on the syringe, because the volume of insulin inject depends on the strength, that is, the number of IU/mL. For this reason, you should always use a syringe marked for the strength of insulin injected. Failure to use the proper syringe can lead to a mistake in dosage, causing serious problems, such as a blood glucose level that is too low or too high.
Syringe Use: To help avoid contamination and possible infection, follow these instructions exactly.
Disposable syringes and needles should be used only once and then discarded.
Needles and Syringes must not be shared.
Preparing the Dose: 1. Wash your hands.
2. Inspect the insulin.
Regular Insulin Human (rDNA origin) (Humulin R) should look clear and colorless. Do not use if it appears cloudy, thickened, or slightly colored or if solid particles are visible.
3. If using a new bottle, flip off the plastic protective cap, but do not remove the stopper.
When using a new bottle, wipe the top of the bottle with an alcohol swab.
4. If you are mixing insulins, refer to the instructions for mixing as follows.
5. Draw air into the syringe equal to your insulin dose. Put the needle through rubber top of the insulin bottle and inject the air into the bottle.
6. Turn the bottle and syringe upside down. Hold the bottle and syringe firmly in 1 hand.
7. Making sure the tip of the needle is in the insulin, withdraw the correct dose of insulin into the syringe.
8. Before removing the needle from the bottle, check your syringe for air bubbles which reduce the amount of insulin in it. If bubbles are present, hold the syringe straight up and tap its side until the bubbles float to the top. Push them out with the plunger and withdraw the correct dose.
9. Remove the needle from the bottle and lay the syringe down so that the needle does not touch anything.
Mixing Humulin: 1. Regular Insulin Human (rDNA origin) (Humulin R) should be mixed with longer-acting human insulins only on the advice the doctor.
Isophane Insulin Human (rDNA origin) (Humulin N) should be mixed only with Regular Insulin Human (rDNA origin) (Humulin R).
2. Draw air into your syringe equal to the amount of longer-acting insulin.
Insert the needle into the longer-acting insulin bottle and inject the air.
Withdraw the needle.
3. Now inject air into the Regular Insulin Human (rDNA origin) (Humulin R) bottle in the same manner, but do not withdraw the needle.
4. Turn the bottle and syringe upside down.
5. Making sure the tip of the needle is in the insulin, withdraw the correct dose of regular insulin into the syringe.
6. Before removing the needle from the bottle, check the syringe for air bubbles which reduce the amount of insulin in it. If bubbles are present, hold the syringe straight up and tap its side until the bubbles float to the top. Push out with the plunger and withdraw the correct dose.
7. Remove the needle from the bottle of Regular Insulin Human (rDNA origin) (Humulin R) and insert it into the bottle of longer-acting insulin. Turn the bottle and syringe upside down. Hold the bottle and syringe firmly in 1 hand and shake gently. Making sure the tip of the needle is in the insulin, withdraw the dose of longer-acting insulin.
8. Remove the needle and lay the syringe down so that the needle does not touch anything.
Follow the doctor's instructions on whether to mix insulins ahead of time or just before giving injection. It is important to be consistent in the method.
Syringes from different manufacturers may vary in the amount of space between the bottom line and the needle. Because of this, do not change: the sequence of mixing, or the model and brand of syringe or needle that the doctor has prescribed.
Injection: Cleanse the skin with alcohol where the injection is to be made. Stabilize the skin by spreading it or pinching up a large area. Insert the needle as instructed by the doctor. Push the plunger in as far as it will go. Pull the needle out and apply gentle pressure over the injection site for several seconds.
Do not rub the area. To avoid tissue damage, give the next injection at a site at least 2 cm from the previous site.
MIMS Class
Insulin Preparations
ATC Classification
A10AB01 - insulin (human) ; Belongs to the class of fast-acting insulins and analogues. Used in the treatment of diabetes.
Presentation/Packing
Inj (cartridge) 100 u/mL x 3 mL x 5's. (vial) 100 u/mL x 10 mL x 1's. KwikPen soln for inj (pre-filled pen, sterile, clear, colorless, aqueous soln) 100 IU/mL x 3 mL x 5's.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in